+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Heart Failure Therapeutics Market by Drug Class (Ace Inhibitors, Arbs, Beta Blockers), Heart Failure Type (Preserved Ejection Fraction, Reduced Ejection Fraction), Mode Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Heart Failure Therapeutics Market by Drug Class (Ace Inhibitors, Arbs, Beta Blockers), Heart Failure Type (Preserved Ejection Fraction, Reduced Ejection Fraction), Mode Of Administration, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Heart Failure Therapeutics Market by Drug Class (Ace Inhibitors, Arbs, Beta Blockers), Heart Failure Type (Preserved Ejection Fraction, Reduced Ejection Fraction), Mode Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5532841
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The heart failure therapeutics market is entering a transformative phase, shaped by demographic changes, evolving clinical needs, and rapid adoption of novel technologies. Senior decision-makers are navigating an increasingly complex environment, where innovation and operational agility are central to sustaining growth and delivering improved patient outcomes.

Market Snapshot: Heart Failure Therapeutics Market

The heart failure therapeutics market grew from USD 26.16 billion in 2024 to USD 29.10 billion in 2025. It is projected to achieve a CAGR of 10.71%, reaching USD 48.18 billion by 2030. This robust growth reflects rising disease prevalence, maturing patient-centric therapies, and greater integration of innovative pharmaceuticals and devices into cardiovascular care pathways.

Scope & Segmentation

  • Drug Classes: ACE inhibitors, ARBs, beta blockers, diuretics, MRAs, SGLT2 inhibitors.
  • Heart Failure Types: Preserved ejection fraction (acute, chronic) and reduced ejection fraction (acute, chronic).
  • Modes of Administration: Intravenous, oral.
  • End Users: Clinics, home care settings, hospitals.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, online platforms.
  • Regional Coverage: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: Novartis International AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Pfizer Inc., Eli Lilly and Company, Bayer AG, Laboratoires Servier, Boston Scientific Corporation, Amgen Inc., Cardurion Pharmaceuticals.

Key Takeaways for Senior Decision-Makers

  • Therapeutic strategies in heart failure increasingly focus on disease-modifying and patient-tailored solutions, surpassing symptomatic relief as a core objective.
  • Integration of digital health technologies such as wearable sensors and remote monitoring systems enables earlier interventions and supports predictive, rather than reactive, clinical management.
  • Pharmaceutical and device convergence, particularly through partnerships for combination therapies and enhanced patient monitoring, is changing competitive positioning among market leaders and new entrants.
  • Adoption patterns for heart failure therapeutics vary significantly across regions, influenced by healthcare infrastructure, regulatory environments, and reimbursement frameworks.
  • Supply chain strategies are increasingly adapting to new tariff and policy measures, driving shifts toward regional manufacturing and stronger inventory management initiatives.

Tariff Impact on Therapeutic Supply Chains

The implementation of United States tariffs in 2025 is introducing new complexities to pharmaceutical and device supply chains. Elevated import costs for active pharmaceutical ingredients are prompting both established firms and contract manufacturers to re-examine sourcing models and explore options such as nearshoring. Investments in domestic production and supply chain resilience are driven by the need to counter price volatility and ensure continuous product availability. While offshore partners leverage economies of scale to remain viable, industry stakeholders are deploying collaborative supply strategies and optimizing workflows to maintain operational continuity.

Methodology & Data Sources

This report is built on a multi-source research framework, including extensive secondary research and structured interviews with industry leaders, cardiologists, and supply chain experts. Diverse data sets—clinical, economic, and strategic—are triangulated to validate trends and segmentation. Rigorous protocols were followed to ensure accuracy, confidentiality, and reliable insight for strategic planning.

Why This Report Matters

  • Empowers senior executives with actionable intelligence to refine growth, supply chain, and partnership strategies within the heart failure therapeutics market.
  • Delivers clarity on the impact of new technologies, regional shifts, and competitive movements essential for informed commercial decisions.
  • Supports proactive adaptation to emerging regulatory and operational risks, including supply chain disruptions and evolving payer requirements.

Conclusion

As global demand for heart failure therapeutics rises, aligning technological innovation with adaptive supply strategies will be critical. Stakeholders leveraging real-world evidence and collaborative market approaches will strengthen leadership in this changing landscape. This report provides a strategic foundation for ongoing success in heart failure care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of SGLT2 inhibitor adoption on heart failure hospitalization rates and payer strategies
5.2. Integration of remote monitoring and telehealth platforms in heart failure management to reduce readmissions
5.3. Development pipeline advancements in cardiac myosin activators for improved systolic function in HFrEF patients
5.4. Market access challenges for novel peptide-based neprilysin inhibitors in congestive heart failure therapy
5.5. Emerging role of biomarkers and personalized medicine in guiding heart failure treatment optimization
5.6. Strategic partnerships between biotech and digital health companies for heart failure remote patient management
5.7. Regulatory landscape evolution and expedited approvals for innovative heart failure therapeutics and diagnostics
5.8. Economic implications of value-based care models on prescription patterns of heart failure drugs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Heart Failure Therapeutics Market, by Drug Class
8.1. Introduction
8.2. Ace Inhibitors
8.3. Arbs
8.4. Beta Blockers
8.5. Diuretics
8.6. Mras
8.7. SGLT2 Inhibitors
9. Heart Failure Therapeutics Market, by Heart Failure Type
9.1. Introduction
9.2. Preserved Ejection Fraction
9.2.1. Acute
9.2.2. Chronic
9.3. Reduced Ejection Fraction
9.3.1. Acute
9.3.2. Chronic
10. Heart Failure Therapeutics Market, by Mode Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Heart Failure Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Heart Failure Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.3. Online
13. Americas Heart Failure Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Heart Failure Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Heart Failure Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis International AG
16.3.2. AstraZeneca PLC
16.3.3. Boehringer Ingelheim International GmbH
16.3.4. Pfizer Inc.
16.3.5. Eli Lilly and Company
16.3.6. Bayer AG
16.3.7. Laboratoires Servier
16.3.8. Boston Scientific Corporation
16.3.9. Amgen Inc.
16.3.10. Cardurion Pharmaceuticals
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HEART FAILURE THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. HEART FAILURE THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. HEART FAILURE THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. HEART FAILURE THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 108. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 109. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 110. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 111. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 118. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 134. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 206. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 207. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 220. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 221. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 222. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 223. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 232. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 249. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 252. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 253. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 254. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 255. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 256. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 257. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 264. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 265. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 268. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 269. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 270. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 271. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 280. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

  • Novartis International AG
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Laboratoires Servier
  • Boston Scientific Corporation
  • Amgen Inc.
  • Cardurion Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 29.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 48.18 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Acute Heart Failure Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Acute Heart Failure Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 96 Pages
  • Global
From
Beta Blockers Market by Product Type (Non-Selective Beta Blockers, Selective Beta Blockers), Route Of Administration (Intravenous, Oral), Distribution Channel, Indication, End User - Global Forecast 2025-2030 - Product Image

Beta Blockers Market by Product Type (Non-Selective Beta Blockers, Selective Beta Blockers), Route Of Administration (Intravenous, Oral), Distribution Channel, Indication, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Dilated Cardiomyopathy Therapeutics Market by Therapeutic Class (Ace Inhibitor, Arb, Arni), Treatment Modality (Device Based, Gene Therapy, Pharmacological), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Dilated Cardiomyopathy Therapeutics Market by Therapeutic Class (Ace Inhibitor, Arb, Arni), Treatment Modality (Device Based, Gene Therapy, Pharmacological), Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Angiotensin Converting Enzyme (ACE) Inhibitors - Global Strategic Business Report - Product Image

Angiotensin Converting Enzyme (ACE) Inhibitors - Global Strategic Business Report

  • Report
  • 169 Pages
  • Global
From
ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.